Garda To Acquire Assertio For $21.80/shr

Assertio Holdings said Garda Therapeutics increased its offer to acquire all outstanding shares to $21.80 per share in cash under an amended merger agreement dated May 1, 2026. The higher bid is a positive development for Assertio shareholders and signals continued takeover interest in the company. The news is company-specific and could support the stock, but the impact is limited to the deal process.

Analysis

Assertio Holdings said Garda Therapeutics increased its offer to acquire all outstanding shares to $21.80 per share in cash under an amended merger agreement dated May 1, 2026. The higher bid is a positive development for Assertio shareholders and signals continued takeover interest in the company. The news is company-specific and could support the stock, but the impact is limited to the deal process.